Heart disease and
stroke are the leading causes of
death and disability among people with Type 2 diabetes. In fact, at least 65
percent of people with diabetes die from some form of heart disease or stroke,
according to the American Heart Association.
However, a new study by researchers at Wake Forest
Baptist Medical Center suggests that the use of cholesterol-lowering statins may
help prolong the lives of people with diabetic cardiovascular disease.
The study is published in the current online edition of
“Although our study was not a clinical trial, it did show
that people with diabetes and heart disease can still live quite a few years by
taking statins,” said Don Bowden, Ph.D., professor of biochemistry at Wake
Forest Baptist and lead author of the study.
The research team studied data from 371 patients who had
participated in the Diabetes Heart Study. At the beginning of the study, the
participants received a CT scan to determine their levels of coronary artery calcium
(CAC); a CAC score greater than 1,000 indicates an increased risk for
cardiovascular disease (CVD).
The team compared the baseline characteristics of 153
patients who died during an average 8.2 years of follow-up and 218 who survived.
The researchers assumed that risk for mortality
would be consistently high among the study participants. However, 60 percent were
still living after more than eight years.
The use of cholesterol-lowering statins at the
baseline exam was the only modifiable risk factor identified to be protective
against mortality. The participants taking statins at the beginning of the
study had a 50 percent increase of being alive as compared to those who didn’t.
Bowden said this highlights the importance of widespread
prescription of cholesterol-lowering medications among individuals with Type 2
diabetes who have existing high CVD risk, but added that in previous studies
the rates of statins prescribed for diabetic patients have been low.
“These data suggest that cholesterol-lowering medications
may be used less than recommended and need to be more aggressively targeted as
a critical modifiable risk factor,” he said.
Funding for the study was provided by National Institutes
of Health grants R01-HL-67348, R01-HL-092301 and R01-N5-058700.
Co-authors of the study are Amanda Cox, Ph.D., Fang-Ci
Hsu, Ph.D., Barry Freedman, M.D., and David Herrington, M.D., of Wake Forest
Baptist; J. Jeffrey Carr, M.D., of Vanderbilt University School of Medicine;
and Michael Criqui, M.D., of the University of California, San Diego.